Stifel analyst Paul Matteis reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY), following announcement of a 3-months delay of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE